Ondansetron
Ondansetron is a pharmaceutical drug with 218 clinical trials. Currently 6 active trials ongoing. Historical success rate of 89.7%.
Success Metrics
Based on 165 completed trials
Phase Distribution
Phase Distribution
32
Early Stage
51
Mid Stage
81
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
86.4%
165 of 191 finished
13.6%
26 ended early
6
trials recruiting
218
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Noninvasive Markers of Functional Nausea in Children
Dexamethasone vs Ondansetron After Cesarean Delivery
Clinical Trials (218)
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Noninvasive Markers of Functional Nausea in Children
Dexamethasone vs Ondansetron After Cesarean Delivery
Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Examining the Effect of Ondansetron on Bowel Prep Success
Cisplatin Disposition and Kidney Injury
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
Comparison Between Intravenous Hydrocortisone and Ondansetron in Prevention of Post Spinal Anesthesia Hypotension
Efficacy and Safety of Ondansetron Versus Metaclopromide Treatment in Infants With Gastro Oesophageal Reflux
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 218